Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP an Autoimmune Disorder That Affects the Peripheral Nerves)

This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.

corticosteroids
prednisone
autoimmune disease
cdas
polyneuropathy
  • 0 views
  • 19 Feb, 2024
Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV)

Mucosal-dominant pemphigus vulgaris (mPV) is a B-cell mediated autoimmune disorder in which painful blisters are formed on the mucosal membrane, including the mouth, nose, throat, eyelids, anus, and genitals.

  • 0 views
  • 19 Feb, 2024
Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis

The aim of this study is to evaluate and compare the efficacy and safety of tofacitinib and methotrexate based on prednisone therapy in patients with Takayasu arteritis

  • 0 views
  • 19 Feb, 2024
Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis

Phase II, single-centre, open label, two parallel arm cohort randomised controlled trial (RCT) testing abatacept in a population of anti-CCP Ab positive individuals at moderate to high risk of developing IA according to a published risk score, already followed in the observational study 'CCP: Next Generation'

tenderness
stiffness
arthritis
abatacept therapy
abatacept
  • 0 views
  • 19 Feb, 2024
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work (MOBILIZE)

The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.

  • 0 views
  • 06 Feb, 2025
Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting

Spermatogonial stem cell transplantation through ultrasound guided rete testis injection and testicular tissue grafting will be performed for participants who have frozen testicular tissue prior to gonadotoxic therapy. The purpose of this study is to test the safety and feasibility of these transplant technologies and restore fertility for these participants.

testicular
autograft
infertility
stem cell transplantation
anesthesia
  • 0 views
  • 19 Feb, 2024
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

Pemphigus is a rare acquired autoimmune disease in which immunoglobulin G (IgG) antibodies target desmosomal proteins to produce intraepithelial, and mucocutaneous blisters.

immunoglobulin
immunomodulators
rituximab
autoimmune disease
prednisolone
  • 0 views
  • 19 Feb, 2024
The Anti-inflammatory Effects of Hark ny Medicinal Water

The study aims to provide evidence on the effectiveness of Harkny medicinal water in psoriatic and rheumatoid arthritis patients using subjective and objective methods. It is a cross-over study, so first half of patients will receive medicinal water, the other half will receive tap water treatment, and after 6 months …

renal disease
psoriasis
skin lesion
psoriasis vulgaris
arthritis
  • 0 views
  • 19 Feb, 2024
Minocycline in MS: Confirmation of Benefit

This is an open-label, single-arm clinical trial. Trial participants will include men and women, aged 18-60 years who have had a first demyelinating event within the previous 180 days and who have brain magnetic resonance imaging (MRI) with at least two brain T2 lesions which are at least 3 mm …

MRI
minocycline
multiple symptoms
health screening
mri brain
  • 0 views
  • 19 Feb, 2024
Autoantibodies Prevalence During Checkpoint Inhibitor Treatment

The use of Checkpoint inhibitors (ICIs) is rapidly expanding to the treatment of many cancer types. Autoimmunity and clinical autoimmune diseases represent adverse events of ICIs with variable severity and consequences. Clinical trials using ICIs have largely excluded patients with preexisting autoimmune diseases but the rate of autoimmune flares has …

  • 0 views
  • 19 Feb, 2024